NCT01712308View on ClinicalTrials.gov

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 21, 2013

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2022

Conditions
AnemiaMyelodysplastic/Myeloproliferative NeoplasmMyelofibrosis
Interventions
BIOLOGICAL

Sotatercept

Given SC

DRUG

Ruxolitinib

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01712308 - Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia | Biotech Hunter | Biotech Hunter